In the past week, RYTM stock has gone down by -1.03%, with a monthly decline of -5.86% and a quarterly plunge of -17.40%. The volatility ratio for the week is 5.87%, and the volatility levels for the last 30 days are 4.94% for Rhythm Pharmaceuticals Inc. The simple moving average for the past 20 days is -2.18% for RYTM’s stock, with a 13.97% simple moving average for the past 200 days.
Is It Worth Investing in Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) Right Now?
Company’s 36-month beta value is 1.98.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for RYTM is 53.99M, and currently, short sellers hold a 18.89% ratio of that floaft. The average trading volume of RYTM on May 08, 2024 was 578.32K shares.
RYTM) stock’s latest price update
Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM)’s stock price has gone decline by -10.32 in comparison to its previous close of 43.88, however, the company has experienced a -1.03% decrease in its stock price over the last five trading days. InvestorPlace reported 2024-05-07 that While conventional wisdom calls for selling securities, these best Nasdaq stocks may require a complete rethink. With the possibility that the Federal Reserve might get its soft landing after all, risk-on sentiment has returned on Wall Street.
Analysts’ Opinion of RYTM
Many brokerage firms have already submitted their reports for RYTM stocks, with Morgan Stanley repeating the rating for RYTM by listing it as a “Overweight.” The predicted price for RYTM in the upcoming period, according to Morgan Stanley is $55 based on the research report published on December 19, 2023 of the previous year 2023.
BofA Securities, on the other hand, stated in their research note that they expect to see RYTM reach a price target of $27, previously predicting the price at $22. The rating they have provided for RYTM stocks is “Buy” according to the report published on August 01st, 2023.
Canaccord Genuity gave a rating of “Buy” to RYTM, setting the target price at $52 in the report published on January 18th of the previous year.
RYTM Trading at -3.98% from the 50-Day Moving Average
After a stumble in the market that brought RYTM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.15% of loss for the given period.
Volatility was left at 4.94%, however, over the last 30 days, the volatility rate increased by 5.87%, as shares sank -9.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -14.73% lower at present.
During the last 5 trading sessions, RYTM fell by -1.03%, which changed the moving average for the period of 200-days by +124.86% in comparison to the 20-day moving average, which settled at $40.02. In addition, Rhythm Pharmaceuticals Inc. saw -14.40% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RYTM starting from German Christopher Paul, who sale 368 shares at the price of $41.76 back on Apr 02 ’24. After this action, German Christopher Paul now owns 795 shares of Rhythm Pharmaceuticals Inc., valued at $15,368 using the latest closing price.
Shulman Joseph, the Chief Technical Officer of Rhythm Pharmaceuticals Inc., sale 18,235 shares at $40.34 during a trade that took place back on Mar 21 ’24, which means that Shulman Joseph is holding 30 shares at $735,600 based on the most recent closing price.
Stock Fundamentals for RYTM
Current profitability levels for the company are sitting at:
- -2.96 for the present operating margin
- 0.88 for the gross margin
The net margin for Rhythm Pharmaceuticals Inc. stands at -2.98. The total capital return value is set at -1.33. Equity return is now at value -85.10, with -51.64 for asset returns.
Based on Rhythm Pharmaceuticals Inc. (RYTM), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -130.42. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -43.49.
Currently, EBITDA for the company is -168.46 million with net debt to EBITDA at 0.2. When we switch over and look at the enterprise to sales, we see a ratio of 25.53. The receivables turnover for the company is 6.26for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.58.
Conclusion
In a nutshell, Rhythm Pharmaceuticals Inc. (RYTM) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
